Cited 43 times in
Transarterial Therapies for Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박영년 | - |
dc.contributor.author | 이형진 | - |
dc.date.accessioned | 2017-11-02T08:11:40Z | - |
dc.date.available | 2017-11-02T08:11:40Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2235-1795 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154183 | - |
dc.description.abstract | BACKGROUND: The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. SUMMARY: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors. KEY MESSAGES: Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | S. Karger | - |
dc.relation.isPartOf | LIVER CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Transarterial Therapies for Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.publisher.location | Switzerland | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pathology | - |
dc.contributor.googleauthor | Ezio Lanza | - |
dc.contributor.googleauthor | Matteo Donadon | - |
dc.contributor.googleauthor | Dario Poretti | - |
dc.contributor.googleauthor | Vittorio Pedicini | - |
dc.contributor.googleauthor | Marco Tramarin | - |
dc.contributor.googleauthor | Massimo Roncalli | - |
dc.contributor.googleauthor | Hyungjin Rhee | - |
dc.contributor.googleauthor | Young Nyun Park | - |
dc.contributor.googleauthor | Guido Torzilli | - |
dc.identifier.doi | 10.1159/000449347 | - |
dc.contributor.localId | A05171 | - |
dc.contributor.localId | A01563 | - |
dc.relation.journalcode | J02170 | - |
dc.identifier.eissn | 1664-5553 | - |
dc.identifier.pmid | 27995085 | - |
dc.subject.keyword | Predictors of response after TAE and TACE for HCC | - |
dc.subject.keyword | TAE and TACE for HCC | - |
dc.contributor.alternativeName | Park, Young Nyun | - |
dc.contributor.alternativeName | Rhee, Hyungjin | - |
dc.contributor.affiliatedAuthor | Rhee, Hyungjin | - |
dc.contributor.affiliatedAuthor | Park, Young Nyun | - |
dc.citation.title | Liver Cancer | - |
dc.citation.volume | 6 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 27 | - |
dc.citation.endPage | 33 | - |
dc.identifier.bibliographicCitation | LIVER CANCER, Vol.6(1) : 27-33, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 42147 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.